(BM) expansion, permit normal development throughout childhood, and extend survival. 1 In
parallel, transfusions re- Early studies of the use of neocytes, or young RBCs, sult in a …

Although epidemiological and biochemical evidence suggests that aluminium may be
associated with Alzheimer's disease (AD), there is no convincing proof of a causal link for …

This aim of this statement is to report an expert consensus on the diagnosis and treatment of
cardiac dysfunction in β-thalassemia major (TM). This consensus statement does not cover …

Background The prognosis of patients with homozygous β-thalassemia (thalassemia major)
has been improved by transfusion and iron-chelation therapy. We analyzed outcome and …

Iron-Chelating Therapy for Transfusional Iron Overload | New England Journal of Medicine Skip
to main content The New England Journal of Medicine homepage Advanced Search SEARCH …

Background Despite the introduction of the parenteral iron chelator desferrioxamine more
than 30 years ago, 50% of patients with thalassaemia major die before the age of 35 years …

Transfusion therapy for inherited anemias and acquired refractory anemias both improves
the quality of life and prolongs survival. A consequence of chronic transfusion therapy is …

Iron overload is a serious clinical condition which can be largely prevented by the use of iron-
specific chelating agents. Desferrioxamine-B, the most widely used iron chelator in …

Iron overload is a serious clinical condition which can be largely prevented by the use of iron‐
specific chelating agents. Desferrioxamine‐B, the most widely used iron chelator in …

Background To determine whether the orally active iron chelator deferiprone (1, 2-dimethyl-
3-hydroxypyridin-4-one) is efficacious in the treatment of iron overload in patients with …